Ride, Run, or Walk for a Future Immune to Cancer Join us on June 10 in West Point, NY!

Clinical Accelerator

Let's spread the word about Immunotherapy! Click to share this page with your community.
Copy Link

The Anna-Maria Kellen Clinical Accelerator is a unique academia-industry partnership model and drug development incubator designed to help organize and de-risk clinical study of next-generation combination cancer immunotherapies.

The program is led by a global network of 80 of the field’s leading clinician-scientists who work collaboratively to identify potentially transformative treatments and to design cutting-edge clinical trials and correlative research efforts to test them. Prioritized studies are launched with a comprehensive set of nonprofit resources and a unique IP model that facilitates access to top drugs from different companies.

Clinical Accelerator currently has more than 15 significant industry and nonprofit partners. The model is powered by a nonprofit venture capital fund that enables it to achieve significant leverage via co-investments, and is structured to become self-sustaining over time via returns on investment back to the charity as supported drugs become successful.

At current, the program invests approximately $20 to $30 million in innovative clinical trials each year. It’s a win-win-win model: Cancer patients gain access to promising new treatment options; Scientists gain extraordinary clinical research and publication opportunities; and Company partners gain valuable investment of nonprofit resources and expertise into their drugs.